Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
delivery system · 1 trial · 1 indication
Percentage of participants who were able to successfully expel the selected dose from the Caverject Impulse Delivery System when relying on the modified Instructions for Use. The process was considered successful if the lower bound of the 95% confidence interval (CI) was more than (\>) 80% overall.
| Arm | Type | Description |
|---|---|---|
| Caverject Impulse | EXPERIMENTAL | representative users |
| Name | Type | Description |
|---|---|---|
| delivery system | OTHER | syringe |
Inclusion Criteria: Age 40 to 70 Exclusion Criteria: Prior syringe skills
Caverject is used for the treatment of Erectile Dysfunction. It is an investigational drug being developed by Pfizer, Inc. and is currently in Phase 3 clinical development. The drug has been studied in a completed clinical trial in the United States.
Caverject is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development for the treatment of Erectile Dysfunction.
Caverject is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Erectile Dysfunction, with one completed Phase 3 trial.
Caverject has been studied in one clinical trial with the identifier NCT01008605, titled 'Caverject User Study'. This was a Phase 3 trial that has been completed, enrolling 48 participants in the United States. The trial was uncontrolled and not randomized or double-blind.
Caverject is also known as delivery system. This alternative name may be used in some contexts, but the drug is primarily referred to as Caverject in clinical development. It is being developed by Pfizer, Inc. for the treatment of Erectile Dysfunction.